Crowell advises Marshall Wace in its investment in Elektrofi
June 21, 2022
Crowell & Moring’s Emerging Companies & Venture Capital team advised Marshall Wace, a global alternative asset manager, in its investment in Elektrofi’s Series B venture capital financing transaction. The deal, which closed on May 27, 2022, marks the latest in a growing number of successful venture investment representations on behalf of Marshall Wace. With this investment, Marshall Wace continues its healthcare crossover fund strategy, which has focused on innovative developers of new biotechnology, medical device applications, and more.
Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, is developing a formulation system to effectively process a wide range of therapeutic molecules. Its technology has the capacity to process large, increasingly complex, and delicate proteins—including monoclonal antibodies, bispecific, and fusion proteins that will enable researchers to discover and modify more advanced medicines. A portion of the proceeds from the financing will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. Elektrofi also plans to strategically double its headcount over the next 12-18 months, in an effort to accelerate development across a growing pipeline of licensed programs with leading pharma and biotech.
The deal team was led by Jon O’Connell, with support from Justin Lurie and Justin Porter.